Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
Healthcare
$5.86 -1.17%
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
52W Low $6.23High $16.44
Volume 3.08M
Average 3.00M
Income Statement
Follow revenue through to earnings.
Revenue
$51.82M
FY 2025 · Annual
-18.7% YoYOperating Income
-$270.02M
FY 2025 · Annual
Net Income
-$265.94M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| 76.39M | 76.88M | 79.83M | 158.27M | 187.24M | |
| 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
OCUL Earnings Waterfall · TTM
NASDAQ:OCUL · Revenue to Net Income
Key Ratios
EPS$-1.46
Gross Margin87.3%
Net Margin-572.7%
P/E Ratio-7.4
P/S Ratio161.8
Analysis
$52.0M of revenue converted into -$290.5M of net income for the selected period. Gross margin is 87.3% and net margin is -572.7%, showing how much revenue survives after costs and taxes. EPS is $-1.46, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 |
How much revenue does OCUL generate?
Ocular Therapeutix, Inc. (OCUL) reported $51.82M of revenue in fiscal 2025.
Is OCUL profitable?
Ocular Therapeutix, Inc. (OCUL) reported -$265.94M of net income, with a net margin of -513.2%.
Continue the stock analysis
Jump to another research area for this company.